Kronos Bio Inc（KRON）の財務KRONKronos Bio Inc

Evaluating the bottom line, Kronos Bio Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -341.95%, while the net margin is -448.71%. These profitability ratios, combined with a Return on Equity (ROE) of -59.49%, provide a clear picture of how effectively KRON converts its operational activities into shareholder value.

In the context of the broader market, KRON competes directly with industry leaders such as HOWL and ATRA. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, KRON's gross margin of 100.00% stands against HOWL's 100.00% and ATRA's 69.68%. Such benchmarking helps identify whether Kronos Bio Inc is trading at a premium or discount relative to its financial performance.